Quality by Design (QbD)-Driven Development and Optimization of Tacrolimus-Loaded Microemulsion for the Treatment of Skin Inflammation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. DoE-oriented optimization of a chitosan-based nanoemulgel of clobetasol propionate for therapeutic intervention in psoriasis.RSC advances · 2026
   Article
2. Injectable Thermoresponsive Dual Nanocarrier Hydrogel for Local Tacrolimus Delivery with a Two-Phase Release Profile.Pharmaceutics · 2026
   Article
3. Quality by design in public healthcare: a rapid development framework for future pandemics.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as